156 related articles for article (PubMed ID: 38699713)
1. Role of MIC levels and 23S rRNA mutation sites to clarithromycin in 14-day clarithromycin bismuth quadruple therapy for
Chen Y; Li S; Li W; Wang Y; Shi J; Xu X; Zhang P; Chen D; Gang R; Luo Q
Heliyon; 2024 Apr; 10(8):e29774. PubMed ID: 38699713
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations.
Kim SJ; Jee SR; Park MI; Jung K; Kim GH; Lee MW; Lee J; Jang JS; Koh M;
Medicine (Baltimore); 2022 Aug; 101(33):e30069. PubMed ID: 35984159
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of H. pylori with bismuth quadruple regimen.
Hsieh MT; Chang WL; Wu CT; Yang HB; Kuo HY; Lin MY; Cheng HC; Tsai YC; Sheu BS
Eur J Clin Pharmacol; 2020 Nov; 76(11):1581-1589. PubMed ID: 32591943
[TBL] [Abstract][Full Text] [Related]
5. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ; Chen PY; Fang YJ; Bair MJ; Chen CC; Chen CC; Yang TH; Lee JY; Yu CC; Kuo CC; Chiu MC; Chou CK; Chen CY; Hu WH; Tsai MH; Hsu YC; Shun CT; Luo JC; Lin JT; El-Omar EM; Wu MS; Liou JM;
Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):623-634. PubMed ID: 37178702
[TBL] [Abstract][Full Text] [Related]
6. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
[TBL] [Abstract][Full Text] [Related]
7. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
8. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of vonoprazan-amoxicillin dual therapy for
Wang X; Teng G; Dong X; Dai Y; Wang W
Therap Adv Gastroenterol; 2023; 16():17562848231190976. PubMed ID: 37664169
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S; Shen W; Liu Y; Dong Q; Shi Y
Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
13. Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin.
Sakinc T; Baars B; Wüppenhorst N; Kist M; Huebner J; Opferkuch W
BMC Res Notes; 2012 Oct; 5():603. PubMed ID: 23110798
[TBL] [Abstract][Full Text] [Related]
14. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
15. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Pan J; Shi Z; Lin D; Yang N; Meng F; Lin L; Jin Z; Zhou Q; Wu J; Zhang J; Li Y
Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Wu Y; Wang Y; Liu X; Liao O; Lou G; Li Y; Wu H; Du Q; Ye J
BMJ Open; 2023 Jul; 13(7):e072670. PubMed ID: 37479526
[TBL] [Abstract][Full Text] [Related]
17. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
[TBL] [Abstract][Full Text] [Related]
18. Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant
Seo SI; Lim H; Bang CS; Yang YJ; Baik GH; Lee SP; Jang HJ; Kae SH; Kim J; Kim HY; Shin WG
Gut Liver; 2022 Sep; 16(5):697-705. PubMed ID: 35145043
[TBL] [Abstract][Full Text] [Related]
19. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
20. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial.
Liang J; Li J; Han Y; Xia J; Yang Y; Li W; Zhang S; Wu Y; Yuan Y; Li Z; Du Y; Chen M; Chen B; Jiang B; Bai Y; Wen Q; Wu K; Fan D
Helicobacter; 2012 Dec; 17(6):458-65. PubMed ID: 23066868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
